Aytu Tops Q1 Estimates as EXXUA Prescriptions Jump 33% Sequentially
AYTU is trading near its 52-week low of $1.75 (4.0% above the low).
Summary
Aytu reported fiscal Q1 revenue of $14.84M against a $13.27M consensus, with the adjusted EBITDA loss narrowing to $2.60M versus the $2.93M loss analysts expected. EXXUA drove the beat, with prescriptions up 33% sequentially, while the ADHD portfolio slipped on reduced promotional emphasis and generic competition and the pediatric portfolio improved on better payer mix and lower returns. Net loss was $3.88M and gross profit $9.44M. The company gave no guidance for future quarters or the full year. The results land alongside the announced Rosemont Pharmaceuticals acquisition at $2.70 a share in cash, which caps the trading relevance of the beat — the stock is now tied to deal completion rather than standalone earnings momentum.
At the time of this announcement, AYTU was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $1.75 to $3.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.